Design Therapeutics, Inc. Share Price

Design Therapeutics, Inc. Share Price

NASDAQ: DSGN | Small Cap
$11.09
+$0.03 (0.23%) Last updated on 30 Oct, 2026 | 01:29 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

Design Therapeutics, Inc. Stock Performance

Open
$11.32
Prev. Close
$11.06
Circuit Range
N/A
Day Range
$10.83 - $11.32
Year Range
$6.20 - $17.20
Volume
16,388
Average Traded
$11.13

Design Therapeutics, Inc. Share Price Today

As of 30 October 2026, Design Therapeutics, Inc.'s share price is $11.09. The stock opened at $11.32, compared to its previous close of $11.06. During today's trading session, Design Therapeutics, Inc.'s share price traded between $10.83 and $11.32, with an average price of $11.07. Over the past 52 weeks, the stock has recorded a high of $17.20 and a low of $6.20. In terms of performance, Design Therapeutics, Inc.'s share price has declined by 18.43% over the last six months and is up 70.35% on a year-on-year basis.

Design Therapeutics, Inc. Share Price Chart

Line chart of the Design Therapeutics, Inc. price trend over the selected period. The price rose overall, ranging from 10.78 to 11.32, ending at 11.08.
$10.83$11.32
L
Show Current Price
H

Design Therapeutics, Inc. Stock Fundamentals & Key Indicators

Market Cap
$635.79M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-1.13
Revenue (TTM)
$0.00
Return On Equity (TTM)
-35.07%
Profit Margin
N/A
Debt to Equity
0.00
Quarterly Earnings Growth YoY
-18.65%

Design Therapeutics, Inc. Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$17.00-$16.00-$17.64-$20.17
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A5.88%-10.25%-14.34%

Design Therapeutics, Inc. Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$0.00$0.00$0.00$0.00
Net Profit-$63.31-$66.86-$49.59-$69.79
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A-5.61%25.83%-40.73%

About Design Therapeutics, Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.

Design Therapeutics, Inc. Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Oct 2026
$12.36
$11.05
-12.16%
Sep 2026
$14.64
$12.58
-17.45%
Aug 2026
$11.92
$15.24
+25.28%
Jul 2026
$14.37
$12.16
-15.75%
Jun 2026
$10.27
$14.44
+37.52%
May 2026
$13.36
$10.50
-22.77%
Apr 2026
$10.87
$13.60
+27.89%
Mar 2026
$10.13
$10.63
+2.41%
Feb 2026
$10.60
$10.38
+1.81%
Jan 2026
$9.27
$10.20
+8.69%
Dec 2025
$9.21
$9.38
+0.11%
Nov 2025
$6.38
$9.37
+43.93%

DSGN Share Price FAQs